Article of the Month – January 2022
January 1, 2022
Owkin
February 1, 2022United Kingdom
Congenica:
Congenica is a digital health company that enables a secure, intuitive, and accredited software platform to support rapid secondary and tertiary analysis of whole genome, whole exome, and gene panel sequencing data. Built on a foundation of clinical expertise, the company empowers users to deliver high-quality genomic medicine services to make decisive clinical decisions. Its use provides life-changing answers to transform patients’ and their families’ lives faster than ever before. Congenica holds exclusivity as the genome-based clinical decision-support solution for the groundbreaking UK NHS Genomic Medicine Service.
Their first national whole genome sequencing program, Genomics at Scale UK 100K GP, delivers genome projects throughout the country. As an exclusive partner for the UK NHS Genomic Medicine Service, it aims for a 50% increase in diagnostic yield, a 95% reduction in manual processing, and the scale of thousands of whole-genome sequencing per week.(1)
Congenica is a digital health company that enables a secure, intuitive, and accredited software platform to support rapid secondary and tertiary analysis of whole genome, whole exome, and gene panel sequencing data. Built on a foundation of clinical expertise, the company empowers users to deliver high-quality genomic medicine services to make decisive clinical decisions. Its use provides life-changing answers to transform patients’ and their families’ lives faster than ever before.
Congenica holds exclusivity as the genome-based clinical decision-support solution for the groundbreaking UK NHS Genomic Medicine Service.Their first national whole genome sequencing program, Genomics at Scale UK 100K GP, delivers genome projects throughout the country. As an exclusive partner for the UK NHS Genomic Medicine Service, it aims for a 50% increase in diagnostic yield, a 95% reduction in manual processing, and the scale of thousands of whole-genome sequencing per week.(1)
Babylon:
The Babylon GP at Hand service provides high-quality NHS primary medical services for people of all ages, regardless of their health status. It is an excellent choice for patients who struggle to attend physical appointments or require care outside office hours. It works with four main parts:
- The knowledge base
- The comprehensive health record
- The probabilistic graphical model
- Simulations(2)
The Babylon GP at Hand service provides high-quality NHS primary medical services for people of all ages, regardless of their health status. It is an excellent choice for patients who struggle to attend physical appointments or require care outside office hours.
It works with four main parts:
- The knowledge base
- The comprehensive health record
- The probabilistic graphical model
- Simulations(2)
Health Innovation Network:
Health Innovation Network South London provides innovative clinics to promote information technologies in the UK. It focuses on primary care centers and hospitals engaged in long-term care. Some breakthrough systems are remote EKG monitoring, an atrial fibrillation identification system, programs to reduce cerebral palsy, and a pain management system for knee osteoarthritis. (3)
Health Innovation Network South London provides innovative clinics to promote information technologies in the UK. It focuses on primary care centers and hospitals engaged in long-term care. Some breakthrough systems are remote EKG monitoring, an atrial fibrillation identification system, programs to reduce cerebral palsy, and a pain management system for knee osteoarthritis. (3)
BIOS
BIOS has developed a fantastic interface between the human nervous system and machines combining hardware and software. The program, which extracted the signals regulating physiological biomarkers using its neural interface, offers a new way of addressing a broad spectrum of conditions.
Their mission is to unlock the nervous system’s potential to treat chronic disease using AI-powered interfaces to automatically read and write neural signals. The BIOS Autonomic Therapy Initiative (BIOS ATI) will be the first deployment in their next-generation neural interface technology to treat heart disease directly via the nervous system. The idea is that patients will have their chronic conditions managed via the nervous system by AI, giving personalized, real-time treatment recommendations and even replacing current drugs with computer-generated neural signals.(4)
BIOS has developed a fantastic interface between the human nervous system and machines combining hardware and software. The program, which extracted the signals regulating physiological biomarkers using its neural interface, offers a new way of addressing a broad spectrum of conditions.
Their mission is to unlock the nervous system’s potential to treat chronic disease using AI-powered interfaces to automatically read and write neural signals. The BIOS Autonomic Therapy Initiative (BIOS ATI) will be the first deployment in their next-generation neural interface technology to treat heart disease directly via the nervous system. The idea is that patients will have their chronic conditions managed via the nervous system by AI, giving personalized, real-time treatment recommendations and even replacing current drugs with computer-generated neural signals.(4)
Health IQ
Health IQ supports the pharmaceutical and life sciences industries in assisting their customers (NHS commissioners, providers, and public health bodies) with intelligence and insight-based solutions to heighten care. Furthermore, it counsels customers by demonstrating evidence-based benefits of their products, both in economic and clinical outcomes, including establishing value and determining results with robust, credible data.(5)
Health IQ supports the pharmaceutical and life sciences industries in assisting their customers (NHS commissioners, providers, and public health bodies) with intelligence and insight-based solutions to heighten care.
Furthermore, it counsels customers by demonstrating evidence-based benefits of their products, both in economic and clinical outcomes, including establishing value and determining results with robust, credible data.(5)
Imperial College London:
The Imperial College of London developed an AI program that identifies breast cancer through imaging. Its accuracy is similar to expert radiologists and supports decision-making while reducing the workload of clinical staff. The UK dataset included mammograms from 25,856 women screened on the NHS at three NHS hospital trusts as part of the Cancer Research UK-funded OPTIMAM project. Although the set comprised medical history and notes, data was depersonalized by removing any information that could identify an individual.(6)
The Imperial College of London developed an AI program that identifies breast cancer through imaging. Its accuracy is similar to expert radiologists and supports decision-making while reducing the workload of clinical staff.
The UK dataset included mammograms from 25,856 women screened on the NHS at three NHS hospital trusts as part of the Cancer Research UK-funded OPTIMAM project. Although the set comprised medical history and notes, data was depersonalized by removing any information that could identify an individual.(6)
Cambridge Cancer Genomics:
Cambridge Cancer Genomics tackles the emerging field of medical genomics and offers much potential. Artificial intelligence techniques provide the most definitive solution to analyze the volume of data needed per patient.
Cambridge Cancer Genomics researches cutting-edge machine learning and cancer genomics to increase the amount of data available to oncologists. The more data the oncologists have, the wiser their decisions about personalized management and therapies. Their approach differs from Congenica in that they focus solely on cancer rather than the full range of diseases.(7)
Cambridge Cancer Genomics tackles the emerging field of medical genomics and offers much potential. Artificial intelligence techniques provide the most definitive solution to analyze the volume of data needed per patient.
Cambridge Cancer Genomics researches cutting-edge machine learning and cancer genomics to increase the amount of data available to oncologists. The more data the oncologists have, the wiser their decisions about personalized management and therapies. Their approach differs from Congenica in that they focus solely on cancer rather than the full range of diseases.(7)
Kheiron:
Kheiron Medical Technologies is a rapidly growing company first to receive a CE Mark in deep learning and radiology. They use deep learning technology to detect breast cancer earlier. Their solution uses image recognition combined with insight from radiologists to detect malignancies in mammograms. Having a machine as one of the “double readers” enables healthcare providers to deliver state-of-the-art services at reduced costs. Their technology is currently under trial in the United Lincolnshire Hospitals Trust and Nottingham University Hospitals Trust.(8)
Kheiron Medical Technologies is a rapidly growing company first to receive a CE Mark in deep learning and radiology. They use deep learning technology to detect breast cancer earlier. Their solution uses image recognition combined with insight from radiologists to detect malignancies in mammograms.
Having a machine as one of the “double readers” enables healthcare providers to deliver state-of-the-art services at reduced costs. Their technology is currently under trial in the United Lincolnshire Hospitals Trust and Nottingham University Hospitals Trust.(8)
LabGenius:
LabGenius develops next-generation protein therapeutics using a machine learning-driven evolution engine (EVA). Robotic automation, synthetic biology, and advanced machine learning are the lab’s cardinal methods to explore the protein fitness landscape. This approach exemplifies evolving a historically artisanal experimental design process into a thorough, rapid, computer-led one. The solution reduces the challenge of creating high-potency drugs with protease stability or extensive tissue penetration. Their first commercial partnership with Tillots Pharma AG searches for new agents to treat inflammatory bowel disease. (9)
LabGenius develops next-generation protein therapeutics using a machine learning-driven evolution engine (EVA). Robotic automation, synthetic biology, and advanced machine learning are the lab’s cardinal methods to explore the protein fitness landscape.
This approach exemplifies evolving a historically artisanal experimental design process into a thorough, rapid, computer-led one. The solution reduces the challenge of creating high-potency drugs with protease stability or extensive tissue penetration. Their first commercial partnership with Tillots Pharma AG searches for new agents to treat inflammatory bowel disease. (9)
Blue Patient
Blue Patient’s software is used in healthcare by inputting patients’ medical data to receive accurate interpretation in real-time. Using an AI algorithm, the program predicts health status to speed up clinical analysis and diagnosis. It saves doctors and pharmacies significant time to be better spent on patient care and result interpretation. All the data used by the Blue Patient algorithm is endorsed by the UK’s National Health Service (NHS).(10)
References